Clinical Trial Detail

NCT ID NCT03983824
Title Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

acute myeloid leukemia

Therapies

Cytarabine + Etoposide + Mitoxantrone + MSC2490484A

Age Groups: adult senior

No variant requirements are available.